Evergreen Capital Management LLC Invests $364,000 in Hims & Hers Health, Inc. $HIMS

Key Points

• Evergreen Capital Management LLC has made a new investment of approximately $364,000 in Hims & Hers Health, acquiring 12,328 shares during the first quarter.
• Hims & Hers Health reported earnings of $0.17 per share for the recent quarter, which was below analysts' expectations, alongside a revenue of $544.83 million, marking a 72.6% increase year-over-year.
• Insider trading reports show significant stock sales, including CEO Andrew Dudum selling 128,127 shares valued at approximately $5.77 million, resulting in a 58.87% decrease in his ownership.

Evergreen Capital Management LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,328 shares of the company's stock, valued at approximately $364,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. UMB Bank n.a. lifted its stake in Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Hims & Hers Health during the first quarter worth $41,000. Larson Financial Group LLC lifted its stake in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after purchasing an additional 458 shares during the last quarter. Fifth Third Bancorp lifted its stake in Hims & Hers Health by 165.4% during the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after purchasing an additional 961 shares during the last quarter. Finally, Tsfg LLC acquired a new position in shares of Hims & Hers Health during the first quarter worth $46,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Up 0.6%

NYSE HIMS traded up $0.28 during trading hours on Friday, hitting $48.39. The company's stock had a trading volume of 24,006,280 shares, compared to its average volume of 22,830,452. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98. The company has a market capitalization of $10.94 billion, a PE ratio of 60.49, a price-to-earnings-growth ratio of 3.27 and a beta of 2.14. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The company's 50-day simple moving average is $50.03 and its two-hundred day simple moving average is $45.25.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health's revenue was up 72.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, insider Michael Chi sold 2,100 shares of the firm's stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $57.52, for a total transaction of $120,792.00. Following the completion of the sale, the insider owned 278,654 shares in the company, valued at $16,028,178.08. This trade represents a 0.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $45.06, for a total transaction of $5,773,402.62. Following the completion of the transaction, the chief executive officer directly owned 89,521 shares of the company's stock, valued at approximately $4,033,816.26. This trade represents a 58.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,390,328 shares of company stock worth $71,468,298 over the last 90 days. Corporate insiders own 13.71% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HIMS. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Wall Street Zen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Morgan Stanley reissued an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research report on Monday, June 23rd. Two investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Reduce" and a consensus target price of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.